Altimmune Says Topline Data From RECLAIM Phase 2 Trial Of Pemvidutide For Alcohol Use Disorder Met Its Primary Endpoint Showing Statistically Significant Reduction In Heavy Drinking Days Vs. Placebo
Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met, including two-level
Altimmune's new medicine tested on people with drinking problems worked better than a fake pill at helping them drink less heavily. When a medicine passes this kind of test, it means the company got one step closer to selling it, which is good news for the business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.